Twenty-five years of statins: where do we go from here?

Q Medicine

Clinical Lipidology Pub Date : 2015-02-01 DOI:10.2217/clp.14.62

A. Gotto, Jennifer E. Moon

引用次数: 2

Abstract

Abstract More than 25 years of clinical trial data have established statins as first-line therapy for the prevention and treatment of atherosclerotic cardiovascular disease. With regard to low-density lipoprotein cholesterol, a wealth of evidence indicates that ‘lower is better,’ although recent guidelines from the American College of Cardiology and the American Heart Association take a different approach. A variety of approved and experimental lipid-lowering agents may be used as supplements or alternatives to statin therapy in patient subgroups, including those with familial hypercholesterolemia, mixed dyslipidemia or statin intolerance. Strategies to achieve further reductions in low-density lipoprotein cholesterol, target high-density lipoprotein cholesterol and triglycerides or reduce inflammation may help address residual cardiovascular risk, although early lifestyle interventions are crucial to prevention strategies.

查看原文本刊更多论文

25年的他汀类药物:我们该何去何从?

超过25年的临床试验数据表明，他汀类药物是预防和治疗动脉粥样硬化性心血管疾病的一线药物。关于低密度脂蛋白胆固醇，大量证据表明“越低越好”，尽管美国心脏病学会(American College of Cardiology)和美国心脏协会(American Heart Association)最近发布的指南采用了不同的方法。在患者亚组中，包括家族性高胆固醇血症、混合性血脂异常或他汀类药物不耐受的患者，可使用多种经批准的实验性降脂药作为他汀类药物治疗的补充或替代。尽管早期生活方式干预对预防策略至关重要，但进一步降低低密度脂蛋白胆固醇、靶向高密度脂蛋白胆固醇和甘油三酯或减少炎症的策略可能有助于解决残留的心血管风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.